Alzheimer’s Disease
Roche: Graduate I Study
The GRADUATE I clinical study will assess how safe and effective an investigational drug is at slowing the progression of early (also known as ‘prodromal’) or mild Alzheimer’s disease.
Merck: Insomnia in Alzheimer’s Patients Study
This research study is evaluating whether the study medication Suvorexant is safe and effective, compared with placebo, in improving insomnia in patients with insomnia and Alzheimer’s disease. The study medication is approved for certain uses in the U.S. and Japan but is considered investigational for other uses and in other countries.
VTV Therapeutics: Steadfast Study
Closed for Enrollment
The STEADFAST Study is a clinical trial, or research study, that will evaluate a new investigational medication, Azeliragon (TTP488), as an addition to many of the commonly prescribed medications for patients with mild-stage Alzheimer’s disease. Azeliragon works by blocking a receptor in the brain that binds to substances such as amyloid beta, a protein thought to contribute to the symptoms of Alzheimer’s disease.
Merck Sharp & Dohme Corp: EPOCH Study
Closed for Enrollment
The clinical trial will assess the efficacy and safety of verubecestat (MK-8931) compared to placebo during 78 week for Alzheimer’s Disease (AD). Participants may choose to participate in a long term double-blind extension phase for up an additional 260 weeks. Your participation in this study is completely voluntary